Pacer Advisors
IBRX icon

Pacer Advisors’s ImmunityBio IBRX Stock Holding History

Pacer Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51K Buy
+5,786
New +$43.8K ﹤0.01% 2036
2024
Q3 		– Sell
-2,478
Closed -$15.7K – 2616
2024
Q2 		$15.7K Sell
2,478
-3,619
-59% -$23.9K ﹤0.01% 3476
2024
Q1 		$32.7K Buy
+6,097
New +$27.6K ﹤0.01% 3336
2021
Q2 		– Sell
-1,618
Closed -$38K – 1468
2021
Q1 		$38K Buy
+1,618
New +$41.9K ﹤0.01% 1468

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pacer Advisors's IBRX Position: Q2 2026 in Review

Pacer Advisors opened a new position in ImmunityBio (IBRX) in Q2 2026: 5,786 shares worth $51K. The stake represents ﹤0.01% of the portfolio and ranks #2036 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in IBRX as recently as Q2 2024.

Pacer Advisors first reported a position in IBRX in Q1 2021 and has held it in 4 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Pacer Advisors held 5,786 shares of ImmunityBio worth $51K as of Q2 2026.
  • ImmunityBio was a new Pacer Advisors position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2036 holding.
  • Pacer Advisors first reported a position in ImmunityBio in Q1 2021 and has held it in 4 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.